Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus RELA.
ORPHENADRINE CITRATE vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties. Its exact mechanism of action is not fully understood, but it is believed to exert its effects by blocking muscarinic acetylcholine receptors and possibly by acting as an NMDA receptor antagonist. It may also have local anesthetic and antihistaminic properties.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
100 mg orally twice daily. Maximum: 250 mg/day.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14 hours (range 11–20 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Primarily renal excretion of metabolites; less than 10% excreted unchanged. Also undergoes biliary excretion with fecal elimination of conjugates.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant